Noninvasive Imaging Reveals Inhibition of Ovarian Cancer by Targeting CXCL12-CXCR4

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2012 Jan 14

PMID 22241961

Citations 21

Authors

Paramita Ray

Sarah A Lewin

Laura Anne Mihalko

Bradley T Schmidt

Kathryn E Luker

Gary D Luker

Affiliations

Soon will be listed here.

Abstract

Patients with metastatic ovarian cancer continue to have a dismal prognosis, emphasizing the need for new strategies to identify and develop new molecular targets for therapy. Chemokine CXCL12 and its receptor CXCR4 are upregulated in metastatic ovarian cancer cells and the intraperitoneal tumor microenvironment. CXCL12-CXCR4 signaling promotes multiple steps in proliferation and dissemination of ovarian cancer cells, suggesting that targeted inhibition of this pathway will limit tumor progression. To investigate CXCL12-CXCR4 signaling in ovarian cancer and establish effects of inhibiting this pathway on tumor progression and survival, we designed a Gaussia luciferase complementation imaging reporter system to detect CXCL12 binding to CXCR4 in ovarian cancer cells. In cell-based assays, we established that the complementation imaging reporter could detect CXCL12 binding to CXCR4 and quantify specific inhibition of ligand-receptor interaction. We monitored CXCL12-CXCR4 binding and inhibition in a mouse xenograft model of metastatic human ovarian cancer by imaging Gaussia luciferase complementation and assessed tumor progression with firefly luciferase. Bioluminescence imaging studies in living mice showed that treatment with AMD3100, a clinically approved inhibitor of CXCL12-CXCR4, blocked ligand-receptor binding and reduced growth of ovarian cancer cells. Treatment with AMD3100 also modestly improved overall survival of mice with metastatic ovarian cancer. The Gaussia luciferase complementation imaging reporter system will facilitate further preclinical development and optimization of CXCL12-CXCR4 targeted compounds for treatment of ovarian cancer. Our research supports clinical translation of existing CXCR4 inhibitors for molecular therapy for ovarian cancer.

Citing Articles

Location, function and role of stromal cell‑derived factors and possible implications in cancer (Review).

Gong W, Martin T, Sanders A, Jiang A, Sun P, Jiang W Int J Mol Med. 2021; 47(2):435-443.

PMID: 33416125 PMC: 7797432. DOI: 10.3892/ijmm.2020.4811.

CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.

Xue J, Li R, Gao D, Chen F, Xie H Int J Nanomedicine. 2020; 15:5701-5718.

PMID: 32848392 PMC: 7426108. DOI: 10.2147/IJN.S257527.

Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry.

Hum N, Martin K, Malfatti M, Haack K, Buchholz B, Loots G Sci Rep. 2018; 8(1):15013.

PMID: 30302019 PMC: 6178347. DOI: 10.1038/s41598-018-33368-0.

Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase.

Hudson L, Gillette J, Kang H, Rivera M, Wandinger-Ness A Cancers (Basel). 2018; 10(10).

PMID: 30261690 PMC: 6211091. DOI: 10.3390/cancers10100358.

Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.

Jecs E, Miller E, Wilson R, Nguyen H, Tahirovic Y, Katzman B ACS Med Chem Lett. 2018; 9(2):89-93.

PMID: 29456793 PMC: 5807867. DOI: 10.1021/acsmedchemlett.7b00406.

References

Tannous B, Kim D, Fernandez J, Weissleder R, Breakefield X . Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther. 2005; 11(3):435-43. DOI: 10.1016/j.ymthe.2004.10.016. View

Barbolina M, Kim M, Liu Y, Shepard J, Belmadani A, Miller R . Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res. 2010; 8(5):653-64. PMC: 2883461. DOI: 10.1158/1541-7786.MCR-09-0463. View

Luker K, Gupta M, Steele J, Foerster B, Luker G . Imaging ligand-dependent activation of CXCR7. Neoplasia. 2009; 11(10):1022-35. PMC: 2745668. DOI: 10.1593/neo.09724. View

Rattan R, Graham R, Maguire J, Giri S, Shridhar V . Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011; 13(5):483-91. PMC: 3084625. DOI: 10.1593/neo.11148. View

Foussat A, Balabanian K, Amara A, Durand-Gasselin I, Baleux F, Couderc J . Production of stromal cell-derived factor 1 by mesothelial cells and effects of this chemokine on peritoneal B lymphocytes. Eur J Immunol. 2001; 31(2):350-9. DOI: 10.1002/1521-4141(200102)31:2<350::aid-immu350>3.0.co;2-0. View

Zhang W, Navenot J, Haribabu B, Tamamura H, Hiramatu K, Omagari A . A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 2002; 277(27):24515-21. DOI: 10.1074/jbc.M200889200. View

Luker K, Gupta M, Luker G . Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 2008; 23(3):823-34. PMC: 2653984. DOI: 10.1096/fj.08-116749. View

Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R . CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011; 71(16):5522-5534. PMC: 3959864. DOI: 10.1158/0008-5472.CAN-10-3143. View

Hendrix C, Flexner C, MacFarland R, Giandomenico C, Fuchs E, Redpath E . Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000; 44(6):1667-73. PMC: 89930. DOI: 10.1128/AAC.44.6.1667-1673.2000. View

10.

Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K, Umezawa K . Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochem Biophys Res Commun. 2010; 403(1):154-9. DOI: 10.1016/j.bbrc.2010.11.007. View

11.

Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling M . Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia. 2007; 9(10):862-70. PMC: 2040213. DOI: 10.1593/neo.07559. View

12.

Luker K, Mihalko L, Schmidt B, Lewin S, Ray P, Shcherbo D . In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nat Med. 2011; 18(1):172-7. PMC: 3253890. DOI: 10.1038/nm.2590. View

13.

Scotton C, Wilson J, Scott K, Stamp G, Wilbanks G, Fricker S . Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002; 62(20):5930-8. View

14.

Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F . Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer. 2007; 122(1):91-9. DOI: 10.1002/ijc.23083. View

15.

De Clercq E . The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003; 2(7):581-7. DOI: 10.1038/nrd1134. View

16.

Remy I, Michnick S . A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods. 2006; 3(12):977-9. DOI: 10.1038/nmeth979. View

17.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

18.

Zabel B, Wang Y, Lewen S, Berahovich R, Penfold M, Zhang P . Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009; 183(5):3204-11. DOI: 10.4049/jimmunol.0900269. View

19.

Smith M, Luker K, Garbow J, Prior J, Jackson E, Piwnica-Worms D . CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004; 64(23):8604-12. DOI: 10.1158/0008-5472.CAN-04-1844. View

20.

Luker K, Steele J, Mihalko L, Ray P, Luker G . Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene. 2010; 29(32):4599-610. PMC: 3164491. DOI: 10.1038/onc.2010.212. View